Profile
Koichiro Tsujimaru was the President & Director of DNAFORM KK, Director of AQUA Therapeutics Co., Ltd., and Principal at Nippon Sanso Holdings Corp.
He holds a doctorate degree from Osaka Prefecture University, which was conferred in 2007.
Former positions of Koichiro Tsujimaru
| Companies | Position | End |
|---|---|---|
AQUA Therapeutics Co., Ltd.
 AQUA Therapeutics Co., Ltd. Pharmaceuticals: MajorHealth Technology AQUA Therapeutics Co., Ltd. develops therapeutic drugs focused on the treatment of ophthalmological diseases. It uses a nucleic acid interference platform aimed at gene targets of select diseases. The firm's technologies include diabetic retinopathy, Periostin, and Bonac nucleic acid. It also offers research, development, manufacture, and marketing of other pharmaceuticals; non-medicinal products and cosmetics; and medical devices, instruments, and equipment. The firm also conducts medical research and consulting services. The company was founded by Kazunori Yoshikawa on March 19, 2012 and is headquartered in Kobe, Japan. | Director/Board Member | - |
| NIPPON SANSO HOLDINGS CORPORATION | Corporate Officer/Principal | - |
DNAFORM KK
 DNAFORM KK Miscellaneous Commercial ServicesCommercial Services DNAFORM KK provides research and development for transcriptome analysis and cloning. Its products and services include solutions for gene expression analysis, DNA/RNA amplification, custom eprobe/eprimer, cDNA clones and other genetic resources. The company was founded in September 1998 and is headquartered in Yokohama, Japan. | President | - |
Training of Koichiro Tsujimaru
| Osaka Prefecture University | Doctorate Degree |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Listed companies | 1 |
|---|---|
| NIPPON SANSO HOLDINGS CORPORATION | Process Industries |
| Private companies | 2 |
|---|---|
DNAFORM KK
DNAFORM KK Miscellaneous Commercial ServicesCommercial Services DNAFORM KK provides research and development for transcriptome analysis and cloning. Its products and services include solutions for gene expression analysis, DNA/RNA amplification, custom eprobe/eprimer, cDNA clones and other genetic resources. The company was founded in September 1998 and is headquartered in Yokohama, Japan. | Commercial Services |
AQUA Therapeutics Co., Ltd.
AQUA Therapeutics Co., Ltd. Pharmaceuticals: MajorHealth Technology AQUA Therapeutics Co., Ltd. develops therapeutic drugs focused on the treatment of ophthalmological diseases. It uses a nucleic acid interference platform aimed at gene targets of select diseases. The firm's technologies include diabetic retinopathy, Periostin, and Bonac nucleic acid. It also offers research, development, manufacture, and marketing of other pharmaceuticals; non-medicinal products and cosmetics; and medical devices, instruments, and equipment. The firm also conducts medical research and consulting services. The company was founded by Kazunori Yoshikawa on March 19, 2012 and is headquartered in Kobe, Japan. | Health Technology |
- Stock Market
- Insiders
- Koichiro Tsujimaru
